Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients

Bjørn Hylsebeck Ebdrup, Filip Krag Knop, Anna Madsen, Henrik Bindesbøl Mortensen, Birgitte Søgaard, Jens J Holst, Pal Bela Szecsi, Henrik H. Lublin

20 Citations (Scopus)


Treatment with antipsychotic drugs is widely associated with metabolic side-effects such as overweight and disturbed glucose metabolism, but the pathophysiological mechanisms are unclear.

Fifty-one non-diabetic, antipsychotic-treated male patients ((mean±standard deviation) age: 33.1 ±6.7 years; body mass index (BMI) 26.0 ±4.7 kg/m2; waist circumference: 95.8 ±13.2 cm; glycated hemoglobin (HbA1c): 5.7 ±0.3%) and 93 age and waist circumference-matched healthy male controls (age: 33 ±7.3 years; BMI: 26.1 ±3.9 kg/m2; waist circumference: 94.6 ±11.9 cm; HbA1c: 5.7 ±0.3%) participated in this cross-sectional study. Blood was sampled in the fasting state and 90 min after ingestion of a standardized liquid meal (2,268 kJ).

Compared to healthy controls, patients were characterized by elevated fasting levels of glucose, proinsulin, C-peptide and glucose-dependent insulinotropic polypeptide (GIP) and higher postprandial levels of insulin, proinsulin, C-peptide and GIP. Also, patients exhibited elevated plasma levels of C-reactive protein and signs of dyslipidemia. Fasting plasma levels of insulin, glucagon, glucagon-like peptide-1 (GLP-1), ghrelin, leptin, adiponectin, tumor necrosis factor-alpha, plasminogen activator inhibitor 1, interleukin 6 and postprandial levels of glucagon, GLP-1, ghrelin, leptin and adiponectin did not differ between groups.

Presenting with an insulin resistant-like pattern, including beta cell hypersecretion and elevated GIP levels, non-diabetic antipsychotic-treated patients display emerging signs of dysmetabolism and a compromised cardiovascular risk profile. The appetite regulating hormones, GLP-1 and ghrelin appear not to be influenced by antipsychotic treatment. Our findings provide new clinical insight into the pathophysiology behind metabolic side-effects of antipsychotics, and put emphasis on the importance of implementing metabolic screening into psychiatric practice.
Original languageEnglish
Publication dateApr 2014
Number of pages1
Publication statusPublished - Apr 2014
Event4th Schizophrenia International Research Society Conference - Firenze Fiera Congress Center, Firenze, Italy
Duration: 5 Apr 20149 Apr 2014


Conference4th Schizophrenia International Research Society Conference
LocationFirenze Fiera Congress Center

Cite this